Study | miR-21 expression2 | Case series | Analytical method |
---|---|---|---|
Volinia et al. [38] | ↑ | 56 PCa; 7 normal prostate tissues from non-cancer individuals | In-house microchip oligonucleotide microarray |
Lu et al. [39] | = | 6 PCa; 8 normal prostate tissues | Bead-based flow cytometry detection system |
Porkka et al. [40] | = | 9 PCa; 4 benign prostatic hyperplasias | In-house oligonucleotide microarray |
Ozen et al. [41] | = | 16 PCa; 10 benign prostatic hyperplasias | miRvana miRNA bioarrays |
Ambs et al. [42] | = | 60 macrodissected PCa; 16 surrounding non-tumor prostate tissues | microRNA microarray (Ohio State University Comprehensive Cancer Center, Version 3.0) |
Leite et al. [43] | = | 18 localized high-grade PCa from radical prostatectomies; 4 metastatic, androgen-independent PCa | TaqMan miRNA qRT-PCR assay |